We find a growing desire among payers to see the appraisal of pharmaceuticals based on cost-effectiveness analysis, like that of ICER, the nation’s self-proclaimed independent watchdog on drug value and pricing. Most payers acknowledge a need to consider ICER reports during their drug evaluation process and many are open to seeing an official U.S. agency conduct cost-effectiveness research.
Neumann U. (2020). The Rise of Cost Effectiveness Considerations in the US. Payer Views and Innovator Strategies. Certara.
Comentários